Systemic Lupus Erythematosus

Bacteremia occurred mostly in patients with active SLE and was frequently associated with severe flares and corticosteroid use.

Construction of a frailty index for patients with systemic lupus erythematosus was feasible as a valid and reliable measure of adverse outcome susceptibility.

The Food and Drug Administration (FDA) has approved the intravenous (IV) formulation of Benlysta (belimumab; GlaxoSmithKline) for the treatment of pediatric patients ≥5 years old with active, autoantibody-positive, systemic lupus erythematosus (SLE) who are receiving standard therapy.

Researchers report the case of a 64-year-old woman with systemic lupus erythematosus and recurrent bilateral stress fractures of the calcaneus due to long-term methotrexate use.

Risk factors included older age, history of mucocutaneous infection, and intravenous or oral steroid therapy.

Researchers investigated how the presence of antidrug antibodies relates to infusion-related reactions and the effectiveness of rituximab therapy in SLE.

The Fatigue Assessment Scale was validated as a reliable and simple tool to assess fatigue in systemic lupus erythematosus.

The development of pulmonary arterial hypertension in patients with SLE is a poor prognostic factor, but systemic hypertension may be a predictive factor for PAH in the SLE population.

EULAR has released updated 2019 recommendations for the management of systemic lupus erythematosus.